EQUITIES

Robust. Fundamental. Dynamic.

Our teams exercise independent thought with high conviction, resulting in portfolios that we believe are well positioned to address our clients' challenges – all within robust risk control frameworks.

vd-icon_Currency_CashUSD

AUD$384.8bn
Equities Assets Under Management

vd-icon_People_3_Group v3

155
Equities Investment
Professionals

vd-icon_Bulleye_Target v3

20
Average Years’ Financial
Industry Experience

As at 31 December 2025

<span class="notranslate">no data</span>

AUD$384.8bn
Equities Assets Under Management

148

155
Equities Investment
Professionals

19

20
Average Years’ Financial
Industry Experience

As at 31 December 2025

We measure success by a single factor: client outcomes. As a pure asset manager, our sole mission is to deliver consistent long-term risk-adjusted returns that exceed our benchmarks and peers, regardless of the prevailing investment landscape.

Featured strategies

All-Cap Emerging Market Equity

A style-agnostic strategy that blends top-down macro analysis with bottom-up stock selection aims to identify attractive opportunities in a volatile asset class.

Global Small Cap

Invests in small companies listed globally, seeking long-term capital growth by identifying good quality but potentially undervalued stocks.

Global Alpha Equity

By investing in global companies across the market-cap and style spectrum, we seek to deliver consistently good risk-adjusted returns, not sporadically great results.

Insights

JH Explorer in Miami: Recovery signs, data centers, and AI risk in industrials

Our Research Analysts share their takeaways from two of the industrials sector’s biggest annual conferences, highlighting which infrastructure themes appear to have staying power.

Data center power: Why the key risk is under delivery, not overbuild

Why the prevailing narrative of new energy-generation capacity exceeding AI data center demand could be off the mark.

Pharma and biotech in 2026: A catalyst‑rich year ahead

With innovation back in focus, a dense slate of drug launches, data readouts, and regulatory decisions makes 2026 a consequential year for pharma and biotech.